aTyr Pharma (LIFE) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
aTyr Pharma Announces First Quarter 2016 Operating Results
May 11, 2016 4:01 PM EDTSAN DIEGO, May 11, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced operating results for the first quarter ended March 31, 2016.
First Quarter Results Â
Research and development expenses were $12.0 million and $6.6 million for the quarters ended March 31, 2016 and 2015, respectively. The increase of $5.4 million was due primarily to a $5.8 million increase related to manufacturing costs and clinical and non-clinical development costs incurred in support... More



